Get it on Google Play

Ardelyx completes enrollment in Phase 3 CIC trial of Ibsrela

November 3, 2026 8:00 AM EST Send to a Friend
Ardelyx, Inc. (Nasdaq: ARDX) announced it has completed enrollment ahead of schedule in its Phase 3 ACCEL clinical trial, evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login